HER2, belonging to the ErbB family of receptor tyrosine kinases, is overexpressed more frequently in pCCAs and dCCAs (17.4%) than in iCCAs (4.8%) and could represent a plausible target in the CCA treatment. The gene discussed is ERBB2; the disease is cholangiocarcinoma.